Next Article in Journal
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
Next Article in Special Issue
Predicting miRNA-Disease Associations by Incorporating Projections in Low-Dimensional Space and Local Topological Information
Previous Article in Journal
A (3D-Nuclear) Space Odyssey: Making Sense of Hi-C Maps
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 10
Issue 6
10.3390/genes10060414
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma

by
Feng Liu
1,†,
Lu Xing
1,†,
Xiaoqian Zhang
2 and
Xiaoqi Zhang
1,*
1
Shandong Provincial Key Laboratory of Oral Tissue Regeneration, School of Stomatology, Shandong University, Jinan 250014, Shandong, China
2
Department of Stomatology, Haiyuan College of Kunming Medical University, Kunming 650000, Yunnan, China
*
Author to whom correspondence should be addressed.
†
These authors contribute equally to this work.
Genes 2019, 10(6), 414; https://doi.org/10.3390/genes10060414
Submission received: 23 April 2019 / Revised: 22 May 2019 / Accepted: 24 May 2019 / Published: 29 May 2019
(This article belongs to the Special Issue Associations Between Non-Coding RNA and Diseases)
Browse Figures
Versions Notes

Abstract

:
Osteosarcoma is a common malignancy with high mortality and poor prognosis due to lack of predictive markers. Increasing evidence has demonstrated that pseudogenes, a type of non-coding gene, play an important role in tumorigenesis. The aim of this study was to identify a prognostic pseudogene signature of osteosarcoma by machine learning. A sample of 94 osteosarcoma patients’ RNA-Seq data with clinical follow-up information was involved in the study. The survival-related pseudogenes were screened and related signature model was constructed by cox-regression analysis (univariate, lasso, and multivariate). The predictive value of the signature was further validated in different subgroups. The putative biological functions were determined by co-expression analysis. In total, 125 survival-related pseudogenes were identified and a four-pseudogene (RPL11-551L14.1, HR: 0.65 (95% CI: 0.44–0.95); RPL7AP28, HR: 0.32 (95% CI: 0.14–0.76); RP4-706A16.3, HR: 1.89 (95% CI: 1.35–2.65); RP11-326A19.5, HR: 0.52(95% CI: 0.37–0.74)) signature effectively distinguished the high- and low-risk patients, and predicted prognosis with high sensitivity and specificity (AUC: 0.878). Furthermore, the signature was applicable to patients of different genders, ages, and metastatic status. Co-expression analysis revealed the four pseudogenes are involved in regulating malignant phenotype, immune, and DNA/RNA editing. This four-pseudogene signature is not only a promising predictor of prognosis and survival, but also a potential marker for monitoring therapeutic schedule. Therefore, our findings may have potential clinical significance.

1. Introduction

Osteosarcoma is the most common malignancy derived from bone, which is originated in mesenchymal tissue like many other sarcomas. It usually occurs in children and young adults as well as the elderly with a typical bimodal distribution in age [1]. The incidence of osteosarcoma is 4.4 per-million among those aged 0–24 years old, and in the second peak of age the disease is usually secondary, accompanied with Paget’s disease or other bony lesions [2]. The primary therapy for osteosarcoma is surgery, but the survival of patients with treatment of surgery alone remains disappointing, around 15–17% [3]. At present, the therapy for osteosarcoma is a combination of chemotherapy and surgery, which could cure about 70% of the patients. For the patients with localized tumor, the reaction of chemotherapy is the best predictor to predict prognosis for now [4]. However, for patients with recurrent or metastatic disease, their overall survival is still not optimistic, which remained at 20% for the last 30 years [5]. Notwithstanding in the advances in surgical techniques, targeted therapy, and tumor immunity, the complications involved with infection and inconvenience resulting from limb-salvage surgery as well as the low survival rates makes it urgent to develop prediction methods for the improvement of survival of osteosarcoma patients [2]. Prognostic biomarkers can provide information about the probable outcome of a cancer relative to disease progression, recurrence, or death [6]. This could provide considerable help with patient stratification, treatment management, and monitoring disease status in clinical practice, such as offering personalized therapeutic schedules for osteosarcoma patients which would benefit enormously [7]. Therefore, it will be very helpful for treatments of osteosarcoma if accompanied by suitable prognostic prediction.
Pseudogenes are a class of homologues of the corresponding functional genes, which are also known as ‘gene fossils’ or ‘junk genes’. They belong to a subclass of long non-coding RNAs [8]. Their inability in expressing functional proteins was because of various mutations in their coding sequences including deletions, insertions, frameshift mutations, etc., which often lead to premature termination of codons [9]. However, pseudogenes can still have numerous regulatory functions by being transcribed into small interference RNAs (siRNAs) [10], competitive endogenous RNA (ceRNA) [11], antisense transcripts [12], and sequestering miRNAs [13]. Studies have shown that aberrant expression of pseudogenes participate in many diseases including cancer [14]. Some cancer related pseudogenes could regulate the expression of their corresponding coding genes such as KRAS and KRASP1, KRAS, and KRASP1 by sequestering the interacting miRNAs [13]. Besides, studies have found aberrant expression of the pseudogenes of transcription factors is critical for maintaining embryonic stem cell pluripotency (i.e., NANOG and NONOGP1, POU5F1P1, and OCT4) in cancer [15]. Some cancer related pseudogenes can be used as biomarkers for prognosis. In hepatocellular carcinoma, high expression level of the pseudogene RP11-564D11.3 is observed to be related with poor prognosis [16], and in another study conducted by Ganapathi et al., they found that pseudogene SLC6A10P can work as a predictive marker for recurrence in high-grade ovarian cancer [17]. However, due to lack of attention and limited number of samples, the potential of pseudogenes as biomarkers for prognosis in osteosarcoma has been not studied.
Recent development in bioinformatics and the availability of large-scale RNA-seq transcriptome data of multiple cancers with clinical follow-up data provide better approaches to explore the biomarkers for diagnosis and prognosis, allowing for a better understanding of the mechanism of cancer and improvement for patients’ outcome [18]. However, most of these studies aimed to construct a diagnosis or prognosis signature are mainly focused on genes, lncRNAs, miRNAs, DNA methylation, as well as alternative splicing [18,19,20,21,22], and pseudogenes’ potential as biomarker has been neglected in osteosarcoma, despite aberrant expression of pseudogenes have been found to be related to multiple pathological processes in cancer and work as a promising biomarker in other types of cancers [23].
In our study, we applied machine learning analysis including univariate cox regression, LASSO cox regression, and multivariate cox regression analysis to construct a pseudogene-based signature to predict the prognosis outcome for osteosarcoma patients. First, by univariate regression, we identified survival related pseudogenes. Next, we narrow down the significantly prognosis related pseudogenes by LASSO regression and multivariate regression, from which we constructed a four-pseudogene based prognostic signature. Then we assessed the clinical utility of this prognostic model and explored its potential functions. Our findings provide new insights into predicting and evaluating the clinical outcome of osteosarcoma patients.

2. Materials and Methods

2.1. Data Acquisition

The osteosarcoma RNA sequencing (RNA-seq) expression data and the corresponding clinical follow-up data were obtained from the public database TARGET (https://ocg.cancer.gov/). In total, there are clinical information of 274 patients and RNA-seq data of 101 patients. TPM is used in this study which is a kind of RNA-seq data scaled by gene length and sequencing depth (M) [24]. After excluding the samples with incomplete information, as well as pseudogenes with low expression (average TPM ≤ 1 across all samples), 94 osteosarcoma expression data of 1333 pseudogenes accompanied by corresponding clinical follow-up information was obtained. The expression value was processed as log2 (TPM + 1) for further analysis [25].

2.2. Construction of Prognostic Signature

Univariate cox regression analysis was performed to screen survival related pseudogenes. The pseudogenes with p-value < 0.05 were screened as candidate pseudogenes for next analysis (FDR for p-value adjustment). These candidate pseudogenes were further screened by LASSO regression, which is an efficient method for regression analysis of high-dimensional predictors [26], and was widely used in Cox proportional hazard regression model for survival analysis [27]. 10-fold cross-validation was conducted to select the tuning parameter to determine the magnitude of penalization, and was then used to choose stable features with nonzero coefficient [28,29,30,31,32]. The coefficients of screened pseudogenes are as following: RP11_551L14.1 (−0.0943699924), RPL7AP28 (−0.1729184112), SRSF9P1 (−0.0077455177), ZC3H11B (0.0326745474), RP4_706A16.3 (0.3262156868), AC079781.5 (0.0161718261), NBPF2P (0.1020104257), TMSB10P2 (−0.0997438836), ZNF815P (−0.0104546653), SLC25A24P1 (0.0271387454), CTA_963H5.5 (−0.0131888444), RP11_241F15.10 (−0.0008593915), RP11_23J18.1 (−0.0168592205), RP11_326A19.5 (−0.2405703963), RP11_344N17.15 (−0.0439379021). Then, multivariate regression analysis was performed and pseudogenes with p < 0.05 was selected for predictive signature construction. Corresponding risk score of each patient was calculated by the formula: risk score = expression of RPL11-551L14.1 × β (−0.4327) + expression of RPL7AP28 × β (−1.1344) + expression of RP4_706A16.3 × β(0.6360) + expression of RP11_326A19.5 × β (−0.6503). Patients were divided into high and low risk groups according to the median risk score (1.23). The Kaplan–Meier (K–M) survival analysis was performed on the two groups. Furthermore, the receiver operating characteristic (ROC) analysis was performed to evaluate the predicting efficiency of the model to predict 3-, 5-, and 8-year survival and the area under curve (AUC) was calculated. All of these processes were conducted by R software (version 3.5.1).

2.3. Nomogram and Calibration

We combined several basic clinical information with the risk score signature to predict the 3-, 5-, and 8-year survival of osteosarcoma patients by plotting nomogram. Calibration plot, which demonstrates whether the predicted outcome is similar with the actual outcome, was used to evaluate the performance of the nomogram. In this section, R package rms was used to plot nomogram and calibration plot.

2.4. Correlation Analysis of the Four Pseudogenes and Annotation of Their Function

The Pearson correlation coefficients between the expression profiles of the four prognostic pseudogenes and protein-coding genes (PCGs) were calculated to determine the co-expression relationships of the pseudogenes and PCGs. The PCGs positively or negatively correlated with the four pseudogenes were considered as pseudogene-related PCGs for functional analysis. The online Database for Annotation, Visualization, and Integrated Discovery (DAVID, https://david.ncifcrf.gov/summary.jsp) [33] was used to explore the functions of pseudogenes-related PCGs and p-value < 0.05 was regarded significant, which is described in detail in our previous studies [19,21,34,35]. The biological processes and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways were presented.

3. Results

3.1. Clinical Characteristics of the Patients

The osteosarcoma cohort includes data from a total of 274 samples. After excluding samples without clinical follow-up information, 94 osteosarcoma patients were involved in this study and the baseline of clinical characters were presented (Table 1). The study flowchart is outlined in Figure 1.

3.2. Identification of Osteosarcoma Survival-Related Pseudogenes

The survival-related pseudogenes were screened using univariate Cox proportional hazards regression analysis. Using p < 0.05 as the cut off, 125 pseudogenes were identified by the univariate analysis as significant to overall survival (Table 2 and Table S1). The top 20 significant survival-related pseudogenes were demonstrated by Forest plot (Figure 2A).

3.3. Construction of the Prognostic Pseudogene Signature for Osteosarcoma

The predictive model was constructed based on the 125 survival-related pseudogenes using LASSO regression. The LASSO Cox regression model was used to select variables in order to avoid overfitting of the predictive model, and 15 pseudogenes with non-zero coefficient were selected with the minimum criteria (Figure 2B,C). Multivariate Cox proportional hazards regression analysis was then performed, and the significant pseudogenes (p < 0.05) were used to construct the model. A four-pseudogene (RPL11-551L14.1, RPL7AP28, RP4-706A16.3, and RP11-326A19.5) based risk model was finally obtained (Figure 2E; Table 3), and a risk-score formula was established according to their expression levels. The four-pseudogene risk score for each patient was calculated, and the patients were divided into high and low risk groups (N = 47 each) according to the median risk score (Figure 2D; Table 4, Table S2).

3.4. Predictive Value of the Four-Pseudogene Signature

Kaplan–Meier survival analysis was performed to assess the potential prognostic value of the four-pseudogene signature, which revealed significantly worse prognosis of the patients in the high-risk group (p < 0.0001; Figure 3A). In addition, ROC analysis was used to determine the accuracy of this signature in predicting the 3-, 5-, and 8-year survival (Figure 3B), and the respective AUCs were 0.885, 0.878, and 0.796, indicating high sensitivity and specificity of this signature. In addition, a higher risk score was associated with shorter survival and more death events (Figure 3C). Taken together, this four-pseudogene signature-based risk model can distinguish the high-risk osteosarcoma patients from the low-risk patients, indicating a prognostic significance for osteosarcoma.

3.5. The Four-Pseudogene Signature Is an Independent Prognostic Predictor of Osteosarcoma

To detect the possible contribution of other factors like age, gender, and metastatic status on patient survival, we also grouped the patients according the above variables, and applied the four-pseudogene signature to different sub-groups. There were 40 males and 54 females in the osteosarcoma cohort, which did not differ significantly in terms of the risk score distribution (Figure 4A). In addition, the high-risk patients had significantly shorter overall survival (OS) (p < 0.01) in both the male and female groups (Figure 4B,C) with respective five-year AUC values of 0.753 and 0.805 (Figure 5A,B), indicating that the four-pseudogene signature was independent of gender. There was also no significant difference in the distribution of the risk score of younger (<18 years, N = 72) and older (>18 years, N = 22) patients (Figure 4D). Furthermore, the low-risk patients had significantly longer OS (p < 0.01; Figure 4E,F), and similar five-year AUC values (0.888 and 0.861; Figure 5C,D) in both age-stratified groups, indicating that the four-pseudogene signature was also independent of age. Based on metastatic status, the patients were divided into non-metastatic and metastatic groups. The both have a similar risk score and a shorter OS in high risk group (Figure 4G–I), and the five-year AUC values were 0.87 and 0.89 for non-metastatic and metastatic respectively (Figure 5E,F), indicating that the four-pseudogene signature was independent of metastatic status. Taken together, the four-pseudogene signature can be applied to osteosarcoma patient subgroups stratified on the basis of clinical characteristics, and is an independent prognostic predictor for osteosarcoma.

3.6. Combined Pseudogene and Clinical Risk Score Is an Independent Predictor of Survival

To combine the basic clinical status (age, gender, site, and metastatic status) with the four-pseudogene signature for predicting patient survival, we constructed a multivariable cox probability hazard model to predict the 3-year, 5-year, and 8-year survival, and visualized it by a nomogram with an assigned score for each term (Figure 6A). Both the forest plot and the nomogram indicated that the risk score is an independent predictor for patient survival (Figure 6B). We also tested the stability and accuracy of the nomogram in terms of agreement between prediction and actual survival. The model performance is shown in Figure 6C and represents perfect prediction.

3.7. Functional Analysis of the Predictive Pseudogenes

Correlation analysis was used to identify the protein coding genes co-expressing with the pseudogenes, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to determine their function. The top 10 correlated PCGs of each pseudogene and their relationship are presented as a network (Figure 7A). The genes with highest correlation to each pseudogene were as follows: RPL11-551L14.1—EHMT2, RPL7AP2 8—HMG20B, RP4-706A16.3—ING5, and RP11—326A19.5—ABHD2 (Figure 7B). The functions of the pseudogenes as per GO (BP, biological process) and KEGG analyses are shown in Figure 7C,D. We found RP11-326A19.5 is associated with cell migration and adhesion such as wound healing, focal adhesion, and pathways in cancer. The RPL11-551L14.1 is participating in regulation of transcription and molecular metabolism. As for RP4-706A16.3, it plays a role in translation of ribosome. Lastly, RPL7AP28 may be related to immune regulation of MHC. A simple summary table for all results was in Table 5.

3.8. Comparison and Combination of Gene-Signature and Pseudogene-Signature

To compare the performance of coding genes as signature with pseudogenes, we used the same method listed in the manuscript, and obtained a two-gene signature predicting the prognosis of osteosarcoma patients (MT1A, HR: 1.41 (95% CI: 1.18–1.69); MPV17L2, HR: 0.39 (95% CI: 0.24–0.65)) (Figure 8A,B). The Kaplan–Meier showed that the two-gene signature can distinguish high risk and low risk patients efficiently. The OS difference between the two groups was significant and high-risk group was associated with worse OS (p < 0.0001) (Figure 8C). ROC analysis revealed that the AUC of the signature predicting the 3-, 5-, and 8-year survival are 0.821, 0.861, and 0.781 respectively (Figure 8D). Compared with the pseudogene model (3-, 5-, and 8-year AUCs were 0.885, 0.878 and 0.796), it seems that the pseudogene-based model has a better performance in our study. Additionally, we combined the gene signature and pseudogene signature together to explore whether the pseudogenes can provide an additional power to the prediction of gene signature or they can work together to give a better performance than alone (Figure 9A). The ROC curve and K–M plot showed that the combined signature can also distinguish the high-risk and low-risk patients and the performance of predicting prognosis is satisfactory (Figure 9B,C). Comparing the three signatures by AUC of ROC curve, the combined signature performed best in sensitivity and specificity in which the AUC is 0.956 (5 years), indicating the genes and pseudogenes can work together to make a better prediction (Figure 9D).

4. Discussion

With the application of chemotherapy in the 1970s, the treatment of osteosarcoma has made great progress. However, survival rate of metastatic and relapse cases remains to be unsatisfactory, and the poor prognosis of such patients is the major problem for osteosarcoma [36]. Thus, identification of novel biomarkers to predict patients’ outcome might help to customize more personalized therapy and would be able to improve their prognosis. Growing evidence supports the role of pseudogenes in the oncogenesis and progression in different cancers [23,37,38] and there are also a few studies which recognized the importance of pseudogenes in osteosarcoma [39,40]. High throughput RNA-seq has paved the way for exploitation of various biomarkers for the diagnosis and prognosis of many cancers including osteosarcoma [18,41,42]. In this study, we took a systematic analysis for the potential role of pseudogenes as prognostic predictor and provided first evidence of survival related pseudogenes of osteosarcoma. We made several important discoveries during the course of this analysis. First, we identified 125 survival-related pseudogenes using univariate Cox analysis, and most of them are risk factors (91/125) which may play the oncogenesis role. Second, we identified a four-pseudogene signature and established a scoring system that was significantly associated with the OS of osteosarcoma patients. This signature helped to stratify the low- and high-risk groups and predicted the OS of osteosarcoma patients with high sensitivity and specificity. Out of four, RP4-706A16.3, is a risk factor and the another three are protective factors. Of the four pseudogenes we have identified, none were reported before, suggesting that these pseudogenes were newly found and required more attention. Third, in order to validate the applicability in different patients and extend the signature to various subgroups, K–M survival analysis and ROC curve analysis were performed in different subgroups. We found that it was independent of other potential predictors—including age, gender, and metastatic status—and the performance of predicting survival was satisfactory. As for the important clinical feature-stage, we did not perform related analysis on it due to the incompleteness of the stage information. Further studies and data are needed to uncover the role of stage. We visualized the pseudogene signature and the other clinical information by a nomogram to simplify the use of this signature in clinical practice. Last, to further understand the biological function and explore the underlying oncogenic mechanism of the four pseudogenes, co-expression analysis was employed. Results showed the four pseudogenes were involved in multiple biological processes and pathways including malignant phenotype, immune, and DNA/RNA editing, which might be the underlying mechanism of osteosarcoma progression. Last, we compared the gene signature and pseudogene signature by ROC curve and found the pseudogene signature is a little better than the gene signature. The AUC of them were very close indicating the two signatures may have similar performance. Maybe the patient sample size leads to these results, a large size cohort is needed to verify this finding.
There are some limitations and shortcomings in this study that cannot be ignored. First, this study was mainly focused on data mining and data analysis, which are based on methodology and the results were not validated using experiments. Further experiments are needed to verify the findings of this study. Second, the datasets we were able to obtain were limited as we could only obtain one osteosarcoma dataset that contained both patient RNA-seq data and clinical follow-up information. If there were another dataset that matched our requirements, it could have been used to further validate our results. Additional datasets should be included to obtain a better result. Besides, there is currently no other study exploiting pseudogene signature for osteosarcoma, meaning that we also cannot validate our result in another independent study. Third, when constructing a pseudogene signature for prognosis, one must take it into consideration of the application of such a model. Since different methods of detecting pseudogenes might lead to different results, the procedure of detection, quantification, and determination of transcriptional activity of pseudogenes must be standardized [43]. Therefore, the four newly found prognosis-related pseudogenes deserve more attention and the next step for our research is to validate our results using experiments. We hope that these results could give other researchers inspiration for further study.

5. Conclusions

Taken together, we identified a novel four-pseudogene signature for osteosarcoma which is a promising independent survival predictor and served as an important biomarker for guiding the clinical treatment of osteosarcoma to improve management for patients. In addition, our findings provide new insights into exploring the underlying molecular mechanisms of osteosarcoma, and present a promising new prognostic marker. Therefore, our findings in the signature have a very promising clinical significance.

Supplementary Materials

The following are available online at https://www.mdpi.com/2073-4425/10/6/414/s1, Table S1: The results of univariate analyses for the significant survival-related pseudogenes, Table S2: The detail of clinical information for the 94 osteosarcoma patients.

Author Contributions

Conceptualization, F.L., L.X., and X.Z. (Xiaoqi Zhang); Data curation, X.Z. (Xiaoqian Zhang); Formal analysis, F.L. and L.X.; Funding acquisition, X.Z. (Xiaoqi Zhang); Methodology, F.L. and L.X.; Project administration, X.Z. (Xiaoqi Zhang); Supervision, X.Z. (Xiaoqi Zhang); Validation, X.Z. (Xiaoqian Zhang); Visualization, X.Z. (Xiaoqian Zhang); Writing—original draft, F.L. and L.X.; Writing—review & editing, X.Z. (Xiaoqi Zhang).

Funding

This research received no external funding.

Acknowledgments

We are grateful for the kind help of Xinhua Liu from Yantai Yuhuangding Hospital and Di Liu from School of Stomatology, Shandong University. Xiaoqi Zhang is very grateful to Minqi Li from Department of Bone Metabolism of School of Stomatology, Shandong University, for his enlightening education, generous help and great support. Xiaoqi Zhang is always appreciating and will thank Minqi Li forever.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AUCArea under curve
BPBiological process
DAVIDDatabase for Annotation, Visualization, and Integrated Discovery
GOGene ontology
KEGGKyoto Encyclopedia of Genes and Genomes
K–MKaplan–Meier
OSOverall survival
PCGsProtein coding genes
ROCReceiver operating characteristic

References

  1. Simpson, S.; Dunning, M.D.; de Brot, S.; Grau-Roma, L.; Mongan, N.P.; Rutland, C.S. Comparative review of human and canine osteosarcoma: Morphology, epidemiology, prognosis, treatment and genetics. Acta Vet. Scand. 2017, 59, 71. [Google Scholar] [CrossRef]
  2. Moore, D.D.; Luu, H.H. Osteosarcoma. Cancer Treat. Res. 2014, 162, 65–92. [Google Scholar] [CrossRef]
  3. Shankar, G.M.; Clarke, M.J.; Ailon, T.; Rhines, L.D.; Patel, S.R.; Sahgal, A.; Laufer, I.; Chou, D.; Bilsky, M.H.; Sciubba, D.M.; et al. The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine: A systematic review with meta-analysis. J. Neurosurg. Spine 2017, 27, 97–104. [Google Scholar] [CrossRef]
  4. Chen, Y.; Gokavarapu, S.; Shen, Q.; Liu, F.; Cao, W.; Ling, Y.; Ji, T. Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival. Oral Oncol. 2017, 73, 124–131. [Google Scholar] [CrossRef]
  5. Kansara, M.; Teng, M.W.; Smyth, M.J.; Thomas, D.M. Translational biology of osteosarcoma. Nat. Rev. Cancer 2014, 14, 722–735. [Google Scholar] [CrossRef] [PubMed]
  6. Ballman, K.V. Biomarker: Predictive or Prognostic? J. Clin. Oncol. 2015, 33, 3968–3971. [Google Scholar] [CrossRef]
  7. Nonaka, T.; Wong, D.T.W. Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. J. Dent. Res. 2018, 97, 701–708. [Google Scholar] [CrossRef] [PubMed]
  8. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489, 57–74. [Google Scholar] [CrossRef] [PubMed]
  9. Pei, B.; Sisu, C.; Frankish, A.; Howald, C.; Habegger, L.; Mu, X.J.; Harte, R.; Balasubramanian, S.; Tanzer, A.; Diekhans, M.; et al. The GENCODE pseudogene resource. Genome Biol. 2012, 13, R51. [Google Scholar] [CrossRef]
  10. Watanabe, T.; Totoki, Y.; Toyoda, A.; Kaneda, M.; Kuramochi-Miyagawa, S.; Obata, Y.; Chiba, H.; Kohara, Y.; Kono, T.; Nakano, T.; et al. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature 2008, 453, 539–543. [Google Scholar] [CrossRef] [PubMed]
  11. Abdollahzadeh, R.; Daraei, A.; Mansoori, Y.; Sepahvand, M.; Amoli, M.M.; Tavakkoly-Bazzaz, J. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer. J. Cell. Physiol. 2019, 234, 10080–10100. [Google Scholar] [CrossRef]
  12. Zhou, B.S.; Beidler, D.R.; Cheng, Y.C. Identification of antisense RNA transcripts from a human DNA topoisomerase I pseudogene. Cancer Res. 1992, 52, 4280–4285. [Google Scholar] [PubMed]
  13. Poliseno, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465, 1033–1038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Pink, R.C.; Wicks, K.; Caley, D.P.; Punch, E.K.; Jacobs, L.; Carter, D.R. Pseudogenes: Pseudo-functional or key regulators in health and disease? RNA 2011, 17, 792–798. [Google Scholar] [CrossRef] [Green Version]
  15. Liu, C.; Guo, T.; Xu, G.; Sakai, A.; Ren, S.; Fukusumi, T.; Ando, M.; Sadat, S.; Saito, Y.; Khan, Z.; et al. Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant. Clin. Cancer Res. 2018, 24, 5123–5132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Song, H.; Yang, J.; Zhang, Y.; Zhou, J.; Li, Y.; Hao, X. Integrated analysis of pseudogene RP11-564D11.3 expression and its potential roles in hepatocellular carcinoma. Epigenomics 2019, 11, 267–280. [Google Scholar] [CrossRef] [PubMed]
  17. Ganapathi, M.K.; Jones, W.D.; Sehouli, J.; Michener, C.M.; Braicu, I.E.; Norris, E.J.; Biscotti, C.V.; Vaziri, S.A.; Ganapathi, R.N. Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer. Int. J. Cancer 2016, 138, 679–688. [Google Scholar] [CrossRef] [PubMed]
  18. He, Y.; Ma, J.; Wang, A.; Wang, W.; Luo, S.; Liu, Y.; Ye, X. A support vector machine and a random forest classifier indicates a 15-miRNA set related to osteosarcoma recurrence. OncoTargets Ther. 2018, 11, 253–269. [Google Scholar] [CrossRef] [PubMed]
  19. Zhang, X.; Feng, H.; Li, Z.; Li, D.; Liu, S.; Huang, H.; Li, M. Application of weighted gene co-expression network analysis to identify key modules and hub genes in oral squamous cell carcinoma tumorigenesis. OncoTargets Ther. 2018, 11, 6001–6021. [Google Scholar] [CrossRef]
  20. Mao, X.; Qin, X.; Li, L.; Zhou, J.; Zhou, M.; Li, X.; Xu, Y.; Yuan, L.; Liu, Q.N.; Xing, H. A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. Gynecol. Oncol. 2018, 149, 181–187. [Google Scholar] [CrossRef]
  21. Zhang, X.; Feng, H.; Li, D.; Liu, S.; Amizuka, N.; Li, M. Identification of differentially expressed genes induced by aberrant methylation in oral squamous cell carcinomas using integrated bioinformatic analysis. Int. J. Mol. Sci. 2018, 19, 1698. [Google Scholar] [CrossRef] [PubMed]
  22. Xing, L.; Zhang, X.; Tong, D. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma. DNA Cell Biol. 2019. [Google Scholar] [CrossRef]
  23. Xiao-Jie, L.; Ai-Mei, G.; Li-Juan, J.; Jiang, X. Pseudogene in cancer: Real functions and promising signature. J. Med. Genet. 2015, 52, 17–24. [Google Scholar] [CrossRef]
  24. Vera Alvarez, R.; Pongor, L.S.; Marino-Ramirez, L.; Landsman, D. TPMCalculator: One-step software to quantify mRNA abundance of genomic features. Bioinformatics 2018, 1–3. [Google Scholar] [CrossRef]
  25. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45, W98–W102. [Google Scholar] [CrossRef]
  26. Sauerbrei, W.; Royston, P.; Binder, H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat. Med. 2007, 26, 5512–5528. [Google Scholar] [CrossRef] [PubMed]
  27. Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 1997, 16, 385–395. [Google Scholar] [CrossRef]
  28. Zhang, J.X.; Song, W.; Chen, Z.H.; Wei, J.H.; Liao, Y.J.; Lei, J.; Hu, M.; Chen, G.Z.; Liao, B.; Lu, J.; et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis. Lancet Oncol. 2013, 14, 1295–1306. [Google Scholar] [CrossRef]
  29. Huang, Y.Q.; Liang, C.H.; He, L.; Tian, J.; Liang, C.S.; Chen, X.; Ma, Z.L.; Liu, Z.Y. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J. Clin. Oncol. 2016, 34, 2157–2164. [Google Scholar] [CrossRef]
  30. Mao, Y.; Dong, L.; Zheng, Y.; Dong, J.; Li, X. Prediction of recurrence in cervical cancer using a nine-lncRNA signature. Front. Genet. 2019, 10, 284. [Google Scholar] [CrossRef] [PubMed]
  31. Ma, S.; Xie, H.; Wang, H.; Han, C.; Yang, J.; Lin, Z.; Li, Y.; He, Q.; Wang, R.; Cui, Y.; et al. MRI-based radiomics signature for the preoperative prediction of extracapsular extension of prostate cancer. J. Magn. Reson. Imaging 2019. [Google Scholar] [CrossRef]
  32. Tian, X.P.; Huang, W.J.; Huang, H.Q.; Liu, Y.H.; Wang, L.; Zhang, X.; Lin, T.Y.; Rao, H.L.; Li, M.; Liu, F.; et al. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. Leukemia 2019. [Google Scholar] [CrossRef]
  33. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [Google Scholar] [CrossRef]
  34. Zhang, X.; Feng, H.; Du, J.; Sun, J.; Li, D.; Hasegawa, T.; Amizuka, N.; Li, M. Aspirin promotes apoptosis and inhibits proliferation by blocking G0/G1 into S phase in rheumatoid arthritis fibroblast-like synoviocytes via downregulation of JAK/STAT3 and NF-kappaB signaling pathway. Int. J. Mol. Med. 2018, 42, 3135–3148. [Google Scholar] [CrossRef]
  35. Zhang, X.; Feng, H.; Li, Z.; Guo, J.; Li, M. Aspirin is Involved in the Cell Cycle Arrest, Apoptosis, Cell Migration, and Invasion of Oral Squamous Cell Carcinoma. Int. J. Mol. Sci. 2018, 19, 2029. [Google Scholar] [CrossRef]
  36. Luetke, A.; Meyers, P.A.; Lewis, I.; Juergens, H. Osteosarcoma treatment—Where do we stand? A state of the art review. Cancer Treat. Rev. 2014, 40, 523–532. [Google Scholar] [CrossRef]
  37. Han, L.; Yuan, Y.; Zheng, S.; Yang, Y.; Li, J.; Edgerton, M.E.; Diao, L.; Xu, Y.; Verhaak, R.G.W.; Liang, H. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat. Commun. 2014, 5, 3963. [Google Scholar] [CrossRef]
  38. De Martino, M.; Forzati, F.; Arra, C.; Fusco, A.; Esposito, F. HMGA1-pseudogenes and cancer. Oncotarget 2016, 7, 28724–28735. [Google Scholar] [CrossRef]
  39. Muller, C.I.; Miller, C.W.; Hofmann, W.K.; Gross, M.E.; Walsh, C.S.; Kawamata, N.; Luong, Q.T.; Koeffler, H.P. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk. Res. 2007, 31, 27–32. [Google Scholar] [CrossRef]
  40. Yan, B.; Wubuli, A.; Liu, Y.; Wang, X. Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway. Exp. Ther. Med. 2018, 15, 4829–4837. [Google Scholar] [CrossRef]
  41. Li, Q.; Li, H.; Zhang, L.; Zhang, C.; Yan, W.; Wang, C. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget 2017, 8, 46136–46144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Li, Y.; Sun, N.; Lu, Z.; Sun, S.; Huang, J.; Chen, Z.; He, J. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017, 393, 40–51. [Google Scholar] [CrossRef] [PubMed]
  43. Guglas, K.; Bogaczynska, M.; Kolenda, T.; Rys, M.; Teresiak, A.; Blizniak, R.; Lasinska, I.; Mackiewicz, J.; Lamperska, K. lncRNA in HNSCC: Challenges and potential. Contemp. Oncol. (Pozn) 2017, 21, 259–266. [Google Scholar] [CrossRef] [PubMed]
Genes 10 00414 g001 550
Figure 1. Flowchart of this study. It exhibits the methods and processes of this study to make it easier for readers to have a better overview of it.
Figure 1. Flowchart of this study. It exhibits the methods and processes of this study to make it easier for readers to have a better overview of it.
Genes 10 00414 g001
Genes 10 00414 g002 550
Figure 2. (A) The forest plot showed the top 20 (20/125) significant survival related pseudogenes through univariate cox analysis. (B) LASSO coefficient profiles of the survival related pseudogenes. A coefficient profile plot was produced against the log lambda sequence. Vertical line was drawn at the value selected using 10-fold cross-validation, where optimal lambda resulted in 15 nonzero coefficients. (C) Tuning parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1-SE criteria). A lambda value of 0.13 was chosen (lambda.min) according to 10-fold cross-validation. (D) Boxplot showed the expression status of the four pseudogenes between high risk and low risk group which divided by median risk score. (E) Forest plot showed results of multivariate cox analysis. Four significant pseudogenes in multivariate cox analysis were screened out (p-value < 0.05) as candidate to construct the risk model.
Figure 2. (A) The forest plot showed the top 20 (20/125) significant survival related pseudogenes through univariate cox analysis. (B) LASSO coefficient profiles of the survival related pseudogenes. A coefficient profile plot was produced against the log lambda sequence. Vertical line was drawn at the value selected using 10-fold cross-validation, where optimal lambda resulted in 15 nonzero coefficients. (C) Tuning parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1-SE criteria). A lambda value of 0.13 was chosen (lambda.min) according to 10-fold cross-validation. (D) Boxplot showed the expression status of the four pseudogenes between high risk and low risk group which divided by median risk score. (E) Forest plot showed results of multivariate cox analysis. Four significant pseudogenes in multivariate cox analysis were screened out (p-value < 0.05) as candidate to construct the risk model.
Genes 10 00414 g002
Genes 10 00414 g003 550
Figure 3. (A) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the four-pseudogene signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (B) ROC analysis of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3-, 5-, and 8-years. (C) The distribution of four-pseudogene risk score, patients’ survival status and pseudogene expression signature were analyzed. As the risk score rising, the patients had a shorter survival time, more death events and the expression value of four pseudogenes ascended or decreased. OS: overall survival.
Figure 3. (A) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the four-pseudogene signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (B) ROC analysis of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3-, 5-, and 8-years. (C) The distribution of four-pseudogene risk score, patients’ survival status and pseudogene expression signature were analyzed. As the risk score rising, the patients had a shorter survival time, more death events and the expression value of four pseudogenes ascended or decreased. OS: overall survival.
Genes 10 00414 g003
Genes 10 00414 g004 550
Figure 4. (A) The dot plot showed the distribution of risk score based four-pseudogene between male (N = 54) and female (N = 40). The risk score is not different between male and female (p-value > 0.05). (B,C) Kaplan–Meier analyses of patients with osteosarcoma in different gender cohorts, grouping based on their gender: male (N = 54), female (N = 40). Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in male cohort and female cohort. (D) The dot plot showed the distribution of risk score based four-pseudogenes between different age group (<18 and ≥18). The risk score is not different between the two groups (p-value > 0.05). (E,F) Kaplan–Meier analyses of patients with osteosarcoma in different age cohorts, grouping based on their age at initial diagnosis: <18 (N = 72), ≥18 (N = 22). Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in <18 and ≥18. (G) The dot plot showed the distribution of risk score based four-pseudogenes between different metastatic status group (non-metastatic = 72 and metastatic = 22). The risk score is not different between the two groups (p-value > 0.05). (H,I) Kaplan–Meier analyses of patients with osteosarcoma in different metastatic status cohorts. Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in metastatic and non-metastatic groups.
Figure 4. (A) The dot plot showed the distribution of risk score based four-pseudogene between male (N = 54) and female (N = 40). The risk score is not different between male and female (p-value > 0.05). (B,C) Kaplan–Meier analyses of patients with osteosarcoma in different gender cohorts, grouping based on their gender: male (N = 54), female (N = 40). Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in male cohort and female cohort. (D) The dot plot showed the distribution of risk score based four-pseudogenes between different age group (<18 and ≥18). The risk score is not different between the two groups (p-value > 0.05). (E,F) Kaplan–Meier analyses of patients with osteosarcoma in different age cohorts, grouping based on their age at initial diagnosis: <18 (N = 72), ≥18 (N = 22). Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in <18 and ≥18. (G) The dot plot showed the distribution of risk score based four-pseudogenes between different metastatic status group (non-metastatic = 72 and metastatic = 22). The risk score is not different between the two groups (p-value > 0.05). (H,I) Kaplan–Meier analyses of patients with osteosarcoma in different metastatic status cohorts. Kaplan–Meier analysis with two-sided log-rank test was performed to estimate the differences in OS between the low-risk and high-risk patients in metastatic and non-metastatic groups.
Genes 10 00414 g004
Genes 10 00414 g005 550
Figure 5. (A,B) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the gender groups. (C,D) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the age groups. (E,F) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the metastatic groups.
Figure 5. (A,B) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the gender groups. (C,D) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the age groups. (E,F) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the metastatic groups.
Genes 10 00414 g005
Genes 10 00414 g006 550
Figure 6. (A) Nomograms combining 4-pseudogene signature and clinical information to predict 3-, 5-, and 8-year survival probability of patients. (B) Forest plot showed results of multivariate cox analysis with 4-pseudogene signature and clinical information. The 4-pseudogene signature is an independent factor (p-value < 0.001). (C) The calibration of each model in terms of agreement between predicted and observed 3-, 5-, or 8-year outcomes. Model performance is shown by the plot, which is highly relative to the 45-degree line, representing perfect prediction.
Figure 6. (A) Nomograms combining 4-pseudogene signature and clinical information to predict 3-, 5-, and 8-year survival probability of patients. (B) Forest plot showed results of multivariate cox analysis with 4-pseudogene signature and clinical information. The 4-pseudogene signature is an independent factor (p-value < 0.001). (C) The calibration of each model in terms of agreement between predicted and observed 3-, 5-, or 8-year outcomes. Model performance is shown by the plot, which is highly relative to the 45-degree line, representing perfect prediction.
Genes 10 00414 g006
Genes 10 00414 g007 550
Figure 7. (A) Network of 4 pseudogenes and their top 10 correlated genes. The correlation between pseudogenes and genes were performed by Pearson correlation analysis. The interaction among genes were generated by STRING database. Yellow dots represent pseudogenes, red dots present positive corelated genes and blue dots represent negative corelated genes. The dot size represents node degree. (B) The representative of corelated genes. The dot plots show the most correlated genes of each pseudogenes. (C) The gene ontology enrichment analysis for the four pseudogenes correlated genes were carried out in DAVID to reveal the potential function of the four pseudogenes. The top five significant biological process terms for each pseudogene were shown. (D) The KEGG pathway enrichment analysis for the four pseudogenes correlated genes were carried out in DAVID to reveal the potential pathways in which the four pseudogenes are involved. The top five significant pathway terms for each pseudogene were shown.
Figure 7. (A) Network of 4 pseudogenes and their top 10 correlated genes. The correlation between pseudogenes and genes were performed by Pearson correlation analysis. The interaction among genes were generated by STRING database. Yellow dots represent pseudogenes, red dots present positive corelated genes and blue dots represent negative corelated genes. The dot size represents node degree. (B) The representative of corelated genes. The dot plots show the most correlated genes of each pseudogenes. (C) The gene ontology enrichment analysis for the four pseudogenes correlated genes were carried out in DAVID to reveal the potential function of the four pseudogenes. The top five significant biological process terms for each pseudogene were shown. (D) The KEGG pathway enrichment analysis for the four pseudogenes correlated genes were carried out in DAVID to reveal the potential pathways in which the four pseudogenes are involved. The top five significant pathway terms for each pseudogene were shown.
Genes 10 00414 g007
Genes 10 00414 g008 550
Figure 8. (A) Tuning parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1-SE criteria). A lambda value of 0.22 was chosen (lambda.min) according to 10-fold cross-validation and 8 genes were identified for further analysis. (B) Forestplot showed results of multivariate cox analysis. Two significant coding genes in multivariate cox analysis were screened out (p_value < 0.05) as candidate to construct the risk model. (C) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the two-coding gene signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (D) ROC analysis of sensitivity and specificity for the two-gene signature in predicting the OS of patients for 3, 5, and 8 years.
Figure 8. (A) Tuning parameter (lambda) selection in the LASSO model used 10-fold cross-validation via minimum criteria. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1-SE criteria). A lambda value of 0.22 was chosen (lambda.min) according to 10-fold cross-validation and 8 genes were identified for further analysis. (B) Forestplot showed results of multivariate cox analysis. Two significant coding genes in multivariate cox analysis were screened out (p_value < 0.05) as candidate to construct the risk model. (C) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the two-coding gene signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (D) ROC analysis of sensitivity and specificity for the two-gene signature in predicting the OS of patients for 3, 5, and 8 years.
Genes 10 00414 g008
Genes 10 00414 g009 550
Figure 9. (A) Forest plot showed results of multivariate cox analysis for the combination model of genes and pseudogenes. (B) ROC analysis of sensitivity and specificity for the combination signature in predicting the OS of patients for 3, 5, and 8 years. (C) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the combination signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (D) ROC analysis of sensitivity and specificity for the comparison among the two-gene signature, four-pseudogene signature, and combination signature in predicting the OS of patients for 5 years and combination signature performed better than the other two.
Figure 9. (A) Forest plot showed results of multivariate cox analysis for the combination model of genes and pseudogenes. (B) ROC analysis of sensitivity and specificity for the combination signature in predicting the OS of patients for 3, 5, and 8 years. (C) The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the combination signature (N = 94). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (p < 0.0001). (D) ROC analysis of sensitivity and specificity for the comparison among the two-gene signature, four-pseudogene signature, and combination signature in predicting the OS of patients for 5 years and combination signature performed better than the other two.
Genes 10 00414 g009
Table
Table 1. Clinical characteristics of patients in osteosarcoma cohort in this study.
Table 1. Clinical characteristics of patients in osteosarcoma cohort in this study.
Alive (n = 57)Dead (n = 37)Total (n = 94)
Gender
FEMALE251540
MALE322254
Age
Mean (SD)15.19 (5.75)14.62 (4.40)14.97 (5.27)
Median (MIN, MAX)15 (3, 39)14 (5, 32)14.5 (3, 39)
Site
Leg/foot533083
other4711
Metastatic status
Metastatic71522
Non-metastatic502272
Table
Table 2. 125 survival related pseudogenes screened by univariate cox regression analysis.
Table 2. 125 survival related pseudogenes screened by univariate cox regression analysis.
PseudogeneHRCI95p-ValuePseudogeneHRCI95p-Value
RP4_706A16.32.141.5–3.052.60 × 10−5RP11_271C24.31.651.07–2.550.023498
RP11_326A19.50.570.43–0.760.000127NCF1C0.610.4–0.940.023523
AC090602.21.551.19–2.020.001094RP11_551L14.10.640.43–0.940.023633
RPL37P61.521.18–1.970.001415RPL23AP531.541.06–2.230.023792
RP11_126D17.11.611.19–2.170.00183ZNF815P0.530.31–0.920.024488
NBPF2P1.841.25–2.710.001885AC002075.41.411.04–1.910.025616
RP11_25I15.11.531.17–20.002111RPL7P471.731.07–2.80.025737
ZC3H11B1.721.21–2.440.002279CTC_451P13.11.491.05–2.110.026269
AP000936.11.621.18–2.210.002517RP11_36C20.11.811.07–3.070.026794
RPS3AP441.961.26–3.050.00281RP11_62J1.30.540.31–0.930.026951
SRSF9P10.350.17–0.70.00321RPL7P91.471.04–2.060.027115
SLC25A24P11.791.22–2.650.003255RP11_10G12.11.451.04–2.010.027132
CTD_2318O12.11.581.15–2.160.004281EEF1A1P111.441.04–1.990.027742
RPS4XP162.291.29–4.070.00472RPL13P120.790.64–0.980.028947
AB019441.292.081.24–3.480.005308RP11_155G14.51.471.04–2.080.029335
CTA_963H5.50.50.3–0.810.005308RPL13AP71.571.04–2.370.030481
ZNF37BP1.821.19–2.770.0055RP11_488L18.41.471.04–2.080.030529
EIF1AXP11.311.08–1.580.005551TMSB4XP80.750.57–0.970.031485
RPL41P21.591.14–2.220.005779FCF1P20.60.38–0.960.031956
PLA2G12AP10.470.27–0.810.006369CSPG4P131.351.03–1.780.03249
RP11_23J18.10.440.24–0.790.006523RPL41P11.091.01–1.170.0327
RP11_535M15.21.831.18–2.830.006615RPL7P231.751.05–2.930.032774
PTGES3P10.50.3–0.830.006904RP11_175B9.31.321.02–1.690.033142
RP11_16F15.21.791.17–2.720.006917RP11_1166P10.11.551.03–2.310.033608
RPL10P31.441.1–1.870.007168SRP68P31.281.02–1.60.034297
RP11_197B12.11.411.1–1.810.007359RP11_51F16.90.570.34–0.960.034541
MTND4P121.31.07–1.570.007377FAM86C2P2.071.05–4.080.034789
RP11_120B7.11.811.16–2.820.008388AC073850.61.411.02–1.940.035167
AC005077.141.421.09–1.830.008434HTR7P10.410.18–0.940.0355
RP11_255H23.51.781.16–2.730.008551CALM2P21.411.02–1.950.035662
RP11_494O16.30.550.35–0.860.008747RP11_587D21.11.341.02–1.760.035695
RP1_95L4.40.460.25–0.820.009153DSTNP20.60.37–0.970.038699
AC010468.11.831.16–2.90.009748AC144530.11.691.03–2.780.039254
MST1L1.661.13–2.440.009936AC004967.71.451.02–2.070.039533
AC079781.51.391.08–1.80.010811NCF1B0.680.46–0.980.039578
HSP90AB2P1.871.15–3.040.011429RP11_381E24.11.641.02–2.630.039904
AC009474.21.451.09–1.930.01172RPS3AP61.461.02–2.080.040027
CTB_75G16.11.761.13–2.740.012065RPL35P20.590.36–0.980.040168
TMSB10P20.640.45–0.910.012102RPL4P42.041.03–4.040.040672
RP3_342P20.21.881.15–3.080.012513HLA_H0.770.6–0.990.040894
HLA_U0.60.41–0.90.012586RPS15AP121.761.02–3.040.041171
RPL7P321.691.12–2.550.01278AC141586.51.571.02–2.440.041404
RP11_302I18.11.961.15–3.320.013077EEF1A1P121.41.01–1.930.041698
RP11_360D2.21.391.07–1.810.013836ANKRD36BP21.391.01–1.90.042281
EEF1A1P11.631.1–2.410.014059U47924.60.670.45–0.990.042954
RP11_20O24.11.491.08–2.050.014879RP11_372E1.11.721.02–2.890.042994
RPS20P221.441.07–1.950.015777RSL24D1P60.560.32–0.980.043269
RP11_583F2.61.51.08–2.080.016158RPS26P311.491.01–2.210.044184
SMG1P11.571.09–2.260.016217GGNBP11.511.01–2.240.044241
RP11_592N21.11.551.08–2.220.016333FAM195CP0.670.45–0.990.044479
SPATA20P10.70.53–0.940.016488EEF1A1P91.321.01–1.740.044928
RP11_501C14.70.550.34–0.90.016961CES5AP11.251–1.550.045574
RPL13AP61.751.1–2.780.017922RP11_553P9.11.611.01–2.570.045933
RPS10L1.651.09–2.490.018544RP11_43F13.11.531.01–2.340.046476
CSAG40.650.45–0.930.019462CTD_2192J16.151.561.01–2.420.046513
TOB2P11.561.07–2.270.019856CH507_42P11.20.670.45–0.990.046872
RP11_344N17.150.60.39–0.920.020105ADCY10P11.51.01–2.250.047079
MLLT10P10.660.47–0.940.020725RP11_761N21.21.331–1.760.04724
ESPNP1.291.04–1.610.021376RP11_736N17.91.291–1.660.047554
RPL7AP280.430.21–0.890.021683RP11_504P24.31.431–2.040.047587
RP11_241F15.100.640.44–0.940.022711RPS26P51.351–1.810.04809
AC011737.21.611.07–2.420.023174REXO1L1P1.451–2.10.048596
RPS11P51.451–2.090.048755
Table
Table 3. Results of multivariate cox regression analysis for the 15 pseudogenes screened by LASSO regression.
Table 3. Results of multivariate cox regression analysis for the 15 pseudogenes screened by LASSO regression.
CharacteristicsHazard RatioCI95p-ValueSignificance
RP11_551L14.10.630.4–0.990.044*
RPL7AP280.420.2–0.890.023*
SRSF9P10.680.3–1.550.36
ZC3H11B1.290.85–1.960.235
RP4_706A16.31.551–2.410.049*
AC079781.51.160.84–1.60.372
NBPF2P1.560.86–2.820.14
TMSB10P20.880.55–1.410.589
ZNF815P0.620.3–1.270.193
SLC25A24P11.350.8–2.30.264
CTA_963H5.50.710.37–1.370.311
RP11_241F15.100.640.4–1.010.057
RP11_23J18.10.910.46–1.780.773
RP11_326A19.50.510.32–0.80.004**
RP11_344N17.150.720.44–1.180.193
Table
Table 4. Score and clinical information of the osteosarcoma cohort.
Table 4. Score and clinical information of the osteosarcoma cohort.
High Risk (47)Low Risk (47)Total (94)
Gender
Female231740
Male243054
Age
Mean (SD)14.8 (5.27)15.13 (5.36)14.97 (5.29)
Median (min,max)14 (5, 39)15 (3, 32)14.5 (3, 39)
Metastatic status
Metastatic15722
Non-metastatic324072
Site
Leg/foot394483
Other8311
Risk score
Mean (SD)5.55 (10.15)0.47 (0.32)3.01 (7.58)
Median (min,max)2.53 (1.23, 66.4)0.5 (0.01, 1.21)1.23 (0.01, 66.4)
Status
Alive283866
Dead19928
Table
Table 5. A simple summary table for results of this article.
Table 5. A simple summary table for results of this article.
Total PGStudied PGSurvival-Related PGSignature-PG
14,12613331254
3Y-AUC5Y-AUC8Y-AUCKM-P-value
Whole patients
0.8850.8780.796<0.0001
Gender subgroup (male)
0.820.8280.7070.0064
Gender subgroup (female)
0.9650.9470.947<0.0001
Age subgroup (<18)
0.9020.8880.788<0.0001
Age subgroup (≥18)
0.8280.8610.7960.038
Metastatic subgroup (non-meta)
0.8710.870.7430.00014
Metastatic subgroup (meta)
0.910.890.89<0.0001
Gene signature
0.8210.8610.781<0.0001
Combined signature
0.9370.9560.871<0.0001
PG: pseudogene; Y: year.

Share and Cite

MDPI and ACS Style

Liu, F.; Xing, L.; Zhang, X.; Zhang, X. A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma. Genes 2019, 10, 414. https://doi.org/10.3390/genes10060414

AMA Style

Liu F, Xing L, Zhang X, Zhang X. A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma. Genes. 2019; 10(6):414. https://doi.org/10.3390/genes10060414

Chicago/Turabian Style

Liu, Feng, Lu Xing, Xiaoqian Zhang, and Xiaoqi Zhang. 2019. "A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma" Genes 10, no. 6: 414. https://doi.org/10.3390/genes10060414

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop